Advertisement
U.S. markets close in 4 hours 30 minutes
  • S&P 500

    5,254.74
    +6.25 (+0.12%)
     
  • Dow 30

    39,762.69
    +2.61 (+0.01%)
     
  • Nasdaq

    16,407.95
    +8.43 (+0.05%)
     
  • Russell 2000

    2,125.79
    +11.44 (+0.54%)
     
  • Crude Oil

    82.57
    +1.22 (+1.50%)
     
  • Gold

    2,235.60
    +22.90 (+1.03%)
     
  • Silver

    25.00
    +0.25 (+1.00%)
     
  • EUR/USD

    1.0804
    -0.0026 (-0.24%)
     
  • 10-Yr Bond

    4.1930
    -0.0030 (-0.07%)
     
  • GBP/USD

    1.2637
    -0.0001 (-0.01%)
     
  • USD/JPY

    151.2190
    -0.0270 (-0.02%)
     
  • Bitcoin USD

    71,068.28
    +1,826.84 (+2.64%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,971.95
    +39.97 (+0.50%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

BioLargo's AOS Filter Lands Its First Canadian Federal Research Grant

SANTA ANA, CA--(Marketwired - Jan 22, 2015) - BioLargo, Inc. (OTCQB: BLGO) announced today that the Natural Sciences and Engineering Research Council of Canada (NSERC) has awarded an "Engage Grant" to Dr. Lynn McMullen at the University of Alberta's Department of Agriculture, Food and Nutritional Sciences to initiate research with BioLargo's Canadian subsidiary BioLargo Water, Inc. The grant will allow dedicated research at the University of Alberta around the company's AOS Filter technology and its electrochemical inactivation of pathogens. This research will provide the necessary fundamental data that can be translated to further applications in the food and agricultural industries.

"This first federal grant gives BioLargo expanded access to the unique knowledge and expertise at the University of Alberta and helps foster our long-term research partnership with the school," commented Dennis Calvert, President & CEO of BioLargo. "This specific award is for the maximum available under the Engage Grant program at $25,000 and we look forward to this important work with Dr. McMullen and to expanding our work at the University of Alberta as additional grants are finalized."

Dr. Lynn McMullen is a Professor of food microbiology at the University of Alberta where she has been teaching for over 20 years. She received her Ph.D. in Food Microbiology from the University of Alberta in 1994. Her primary research focus is on the use of novel techniques to improve the microbial safety and quality of meat and other animal products. She works closely with industry and government organizations to improve meat hygiene and looks forward to her involvement with BioLargo as this research adds an exciting dimension to solving problems in food safety. Dr. McMullen has mentored over 40 graduate students in the past 20 years and the research with BioLargo will lead to the training of more students. We anticipate that the research will allow BioLargo to expand their Advanced Oxidation system to new applications in food and agriculture.

About BioLargo, Inc.
BioLargo, Inc. (OTCQB: BLGO) makes life better by delivering technology-based products that help solve some of the world's most important problems that threaten water, food, agriculture, healthcare and energy. More information can be found about the company and its subsidiaries at www.BioLargo.com. The subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases the Advanced Oxidation Systems, including its AOS Filter, a product in development specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies, It is the winner of the Technology Star award by New Technology Magazine for its breakthrough innovation for the oil industry. BioLargo also owns a 50% interest in the Isan System, which was honored with a "Top 50 Water Company for the 21st Century" award by the Artemis Project. The subsidiary Odor-No-More Inc., features award-winning products serving the pet, equine, and consumer markets, including the Nature's Best Solution® and Deodorall® brands. (www.OdorNoMore.com). The subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com), focuses on advanced wound care management and is preparing to make FDA 510(k) applications in 2015.

Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K for the year ended December 31, 2013.

Advertisement